The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance

Aging (Albany NY). 2016 Feb;8(2):208-9. doi: 10.18632/aging.100907.

Authors

Diana M Willmes^{1

2}, Stephen L Helfand³, Andreas L Birkenfeld^{1

2}

Affiliations

¹ Section of Metabolic Vascular Medicine, Medical Clinic III, Dresden University School of Medicine, Technische Universität Dresden, Dresden, Germany.
² Paul Langerhans Institute Dresden (PLID), German Center for Diabetes Research (DZD), Dresden, Germany.
³ Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI 02912, USA.

No abstract available

Keywords: INDY; Slc13a5; aging; fatty liver; longevity; type 2 diabetes.

Publication types

Letter

MeSH terms

Animals
Fatty Liver / metabolism*
Humans
Insulin Resistance / physiology*
Longevity / physiology
Symporters / metabolism*

Substances

SLC13A5 protein, human
Symporters

Grants and funding

RF1 AG024353/AG/NIA NIH HHS/United States